BACKGROUND: Thyroid dysfunction is a common adverse event associated with tyrosine kinase inhibitors (TKI), but its underlying pathophysiology is unclear. Cabozantinib is a novel TKI currently Food and Drug Administration approved for advanced medullary thyroid cancer and tested in clinical trials on solid tumors including prostate, liver, bladder, breast, and ovarian cancer. METHODS: We analyzed the thyroid function of patients enrolled in two phase 2 clinical trials using cabozantinib at the National Institutes of Health Clinical Center. Two cases of thyroiditis associated with cabozantinib therapy are presented in detail, and a systematic review of the literature on TKI-associated thyroid dysfunction is also discussed. RESULTS: Between September 2012 and September 2013, 33 patients were treated with cabozantinib, and follow-up thyroid function tests were available for 31 (20 males, 11 females; age 59±1 years). Thyroid dysfunction was recorded in the majority of patients (93.1%), with a predominance of subclinical hypothyroidism. Two cases showed a biphasic pattern of thyroid dysfunction characterized by a transient thyrotoxicosis followed by hypothyroidism. Color Doppler demonstrated an increase in vascularization during the thyrotoxic phase, but no uptake was visualized on nuclear medicine imaging. A systematic review of the literature resulted in the identification of 40 original manuscripts, of which 13 were case series and 6 were case reports describing TKI-associated thyroid dysfunction. CONCLUSION: TKI therapy often results in clinically significant thyroid dysfunction. Cabozantinib treatment commonly results in thyroid dysfunction varying from subclinical hypothyroidism to symptomatic thyrotoxicosis. Early detection and characterization of cabozantinib-associated thyroid dysfunction and close follow-up are essential to provide adequate management of this common adverse event.
BACKGROUND:Thyroid dysfunction is a common adverse event associated with tyrosine kinase inhibitors (TKI), but its underlying pathophysiology is unclear. Cabozantinib is a novel TKI currently Food and Drug Administration approved for advanced medullary thyroid cancer and tested in clinical trials on solid tumors including prostate, liver, bladder, breast, and ovarian cancer. METHODS: We analyzed the thyroid function of patients enrolled in two phase 2 clinical trials using cabozantinib at the National Institutes of Health Clinical Center. Two cases of thyroiditis associated with cabozantinib therapy are presented in detail, and a systematic review of the literature on TKI-associated thyroid dysfunction is also discussed. RESULTS: Between September 2012 and September 2013, 33 patients were treated with cabozantinib, and follow-up thyroid function tests were available for 31 (20 males, 11 females; age 59±1 years). Thyroid dysfunction was recorded in the majority of patients (93.1%), with a predominance of subclinical hypothyroidism. Two cases showed a biphasic pattern of thyroid dysfunction characterized by a transient thyrotoxicosis followed by hypothyroidism. Color Doppler demonstrated an increase in vascularization during the thyrotoxic phase, but no uptake was visualized on nuclear medicine imaging. A systematic review of the literature resulted in the identification of 40 original manuscripts, of which 13 were case series and 6 were case reports describing TKI-associated thyroid dysfunction. CONCLUSION: TKI therapy often results in clinically significant thyroid dysfunction. Cabozantinib treatment commonly results in thyroid dysfunction varying from subclinical hypothyroidism to symptomatic thyrotoxicosis. Early detection and characterization of cabozantinib-associated thyroid dysfunction and close follow-up are essential to provide adequate management of this common adverse event.
Authors: Leni van Doorn; Ferry A L M Eskens; Theo J Visser; Aad van der Lugt; Ron H J Mathijssen; Robin P Peeters Journal: Thyroid Date: 2011-02 Impact factor: 6.568
Authors: Mariëtte H W Kappers; Joep H M van Esch; Frank M M Smedts; Ronald R de Krijger; Karel Eechoute; Ron H J Mathijssen; Stefan Sleijfer; Frank Leijten; A H Jan Danser; Anton H van den Meiracker; Theo J Visser Journal: J Clin Endocrinol Metab Date: 2011-08-03 Impact factor: 5.958
Authors: N Shinohara; M Takahashi; T Kamishima; H Ikushima; N Otsuka; A Ishizu; C Shimizu; H Kanayama; K Nonomura Journal: Br J Cancer Date: 2010-12-14 Impact factor: 7.640
Authors: Michael J Fisher; Chie-Schin Shih; Steven D Rhodes; Amy E Armstrong; Pamela L Wolters; Eva Dombi; Chi Zhang; Steven P Angus; Gary L Johnson; Roger J Packer; Jeffrey C Allen; Nicole J Ullrich; Stewart Goldman; David H Gutmann; Scott R Plotkin; Tena Rosser; Kent A Robertson; Brigitte C Widemann; Abbi E Smith; Waylan K Bessler; Yongzheng He; Su-Jung Park; Julie A Mund; Li Jiang; Khadijeh Bijangi-Vishehsaraei; Coretta Thomas Robinson; Gary R Cutter; Bruce R Korf; Jaishri O Blakeley; D Wade Clapp Journal: Nat Med Date: 2021-01-13 Impact factor: 53.440
Authors: Andrea B Apolo; Rosa Nadal; Yusuke Tomita; Nicole N Davarpanah; Lisa M Cordes; Seth M Steinberg; Liang Cao; Howard L Parnes; Rene Costello; Maria J Merino; Les R Folio; Liza Lindenberg; Mark Raffeld; Jeffrey Lin; Min-Jung Lee; Sunmin Lee; Sylvia V Alarcon; Akira Yuno; Nancy A Dawson; Kimaada Allette; Arpita Roy; Dinuka De Silva; Molly M Lee; Tristan M Sissung; William D Figg; Piyush K Agarwal; John J Wright; Yangmin M Ning; James L Gulley; William L Dahut; Donald P Bottaro; Jane B Trepel Journal: Lancet Oncol Date: 2020-07-06 Impact factor: 41.316
Authors: Guan-Nan Zhang; Yun-Kai Zhang; Yi-Jun Wang; Anna Maria Barbuti; Xi-Jun Zhu; Xin-Yue Yu; Ai-Wen Wen; John N D Wurpel; Zhe-Sheng Chen Journal: Pharmacol Res Date: 2017-01-25 Impact factor: 7.658